Enesi Pharma to showcase unique ImplaVax® Needle-Free Solid Dose Vaccine Platform at World Vaccine Congress Europe 2018

Oxford, UK – 4 October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, announces it will showcase its innovative ImplaVax® needle-free solid dose vaccine platform at the upcoming World Vaccine Congress Europe 2018 in Lisbon, Portugal (29-31 October 2018). Enesi Pharma is once again a Silver Sponsor of the event and will also be represented at Booth 28 in the Conference Exhibition.

 In addition, Enesi’s CEO David Hipkiss will Chair two sessions at the Congress: ‘Integrated Bioprocessing & Delivery’ on 30 October from 10:10am; and an interactive Partnerships session on 31 October at 9:00am.

Enesi is focused on the development of innovative vaccines using its proprietary ImplaVax technology, which have the potential to make a material impact on global healthcare. The Company has recently announced collaborations to evaluate opportunities for ImplaVax-enabled vaccines with the Walter Reed Army Institute of Research (Shigella infection) and Public Health England (emergent threat Pathogens, including Anthrax recombinant Protective Antigen (rPA) and Crimean-Congo Haemorrhagic Fever).

ImplaVax is the combination of an innovative and proprietary solid dose formulation and device technology for subcutaneous vaccination offering significant potential benefits for patients, care givers, healthcare professionals and payers. Product benefits are achieved through enhanced effectiveness, safety, ease of use, reliability and thermal stability. ImplaVax products also offer no risk of needle-stick injury or cross-contamination and are supported by a strong patient preference over needle and syringe.